Ascendis Pharma A/s Share Price Today
(NASDAQ: ASND)

Name: Ascendis Pharma A/s Share Price Today (NASDAQ: ASND) - Ascendis Pharma A/s Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Ascendis Pharma A/s share price is $166.05 & ₹14,365.82 as on 20 Mar 2025, 2.30 'hrs' IST

$166.05

▲

1.4

(0.85%)

Market is closed - opens 7 PM, 20 Mar 2025

View live Ascendis Pharma A/s share price in Dollar and Rupees. Guide to invest in Ascendis Pharma A/s stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Ascendis Pharma A/s, along with analyst recommendations, forecasts, and comprehensive financials.

Ascendis Pharma A/s share price movements

Today's Low: $161.25
Today's High: $166.86
$166.05
2.89%
Downside
Day's Volatility :3.36%
Upside
0.49%
52 Weeks Low: $111.09
52 Weeks High: $169.37
$166.05
33.1%
Downside
52 Weeks Volatility :34.41%
Upside
1.96%

Ascendis Pharma A/s (ASND) Returns

Period	Ascendis Pharma A/s	Sector (Health Care)	Index (Russel 2000)
3 Months	20.55%	-9999999.0%	0.0%
6 Months	8.23%	-9999999.0%	0.0%
1 Year	15.13%	-9999999.0%	0.0%
3 Years	48.82%	-9999999.0%	-15.2%

Ascendis Pharma A/s (ASND) Key Statistics

in dollars & INR

Previous Close	$164.65
Open	$164.29
Today's High	$166.86
Today's Low	$161.25
Market Capitalization	$9.9B
Today's Volume	$303.6K
52 Week High	$169.37
52 Week Low	$111.09
Revenue TTM	$363.6M
EBITDA	$-273.8M
Earnings Per Share (EPS)	$-7.11
Profit Margin	-103.97%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-818.43%

How to invest in Ascendis Pharma A/s Stock (ASND) from India?

It is very easy for Indian residents to invest directly in Ascendis Pharma A/s from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Ascendis Pharma A/s stock in both Indian Rupees (INR) and US Dollars (USD). Search for Ascendis Pharma A/s or ASND on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Ascendis Pharma A/s or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Ascendis Pharma A/s shares which would translate to 0.005 fractional shares of Ascendis Pharma A/s as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Ascendis Pharma A/s, in just a few clicks!

Returns in Ascendis Pharma A/s (ASND) for Indian investors in Rupees

The Ascendis Pharma A/s stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Ascendis Pharma A/s investment value today

Current value as on today

₹1,19,196

Returns

₹19,196

(+19.2%)

Returns from Ascendis Pharma A/s Stock

₹15,129 (+15.13%)

Dollar Returns

₹4,068 (+4.07%)

Indian investors sentiment towards Ascendis Pharma A/s (ASND)

97%

Period: Feb 17, 2025 to Mar 19, 2025. Change in 30 Days versus previous period

Search interest for Ascendis Pharma A/s Stock from India on INDmoney has increased by 97% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Ascendis Pharma A/s

RA Capital Management, LLC
16.90%
Westfield Capital Management Company, L.P.
9.24%
venBio Select Advisor LLC
8.53%
FMR Inc
7.90%
Artisan Partners Limited Partnership
7.44%
HHG PLC
7.32%

Analyst Recommendation on Ascendis Pharma A/s

Buy

80%Buy

20%Hold

0%Sell

Based on 20 Wall street analysts offering stock ratings for Ascendis Pharma A/s(by analysts ranked 0 to 5 stars)

Based on 20 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Ascendis Pharma A/s Stock (ASND)

What analysts predicted

Upside of 27.29%

Target:

$211.36

Current:

$166.05

Insights on Ascendis Pharma A/s Stock (Ticker Symbol: ASND)

Price Movement
In the last 1 month, ASND stock has moved up by 7.4%
Increasing Revenue
Ascendis Pharma A/S has shown strong revenue growth over the last three quarters. The revenue increased from $35.99 million to $173.91 million, representing an average growth of 52.3% per quarter.
Increasing Net Profit
Ascendis Pharma A/s has shown a positive trend in its net profit over the last six quarters, moving from a loss of $162.22 million to a smaller loss of $38.46 million. This reflects an average quarterly improvement of 42.4%.
ASND vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 71.3% return, outperforming this stock by 56.2%
ASND vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 53.4% return, outperforming this stock by 12.0%
Price to Sales
Ascendis Pharma A/S has a Price-to-Sales (P/S) Ratio of 26.4, meaning that investors are willing to pay $26.4 for every $1 of sales generated by the company. In comparison, Alnylam Pharmaceuticals, Inc. has a much lower P/S Ratio of 14.4, indicating that investors pay only $14.4 for each $1 of that company's sales. This suggests that investors have a higher valuation for Ascendis Pharma's sales compared to Alnylam Pharmaceuticals.

ASND Ascendis Pharma A/s Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$14.9M	↑ 26.41%
Net Income	$-242.3M	↑ 67.58%
Net Profit Margin	-1.6K%	↓ 400.5%

	FY20	Y/Y Change
Revenue	$8.5M	↓ 48.01%
Net Income	$-509.6M	↑ 92.17%
Net Profit Margin	-6.0K%	↓ 4395.5%

	FY21	Y/Y Change
Revenue	$8.8M	↑ 11.87%
Net Income	$-433.6M	↓ 8.44%
Net Profit Margin	-4.9K%	↑ 1093.97%

	FY22	Y/Y Change
Revenue	$54.2M	↑ 557.93%
Net Income	$-617.2M	↑ 52.04%
Net Profit Margin	-1.1K%	↑ 3791.93%

	FY23	Y/Y Change
Revenue	$291.0M	↑ 421.2%
Net Income	$-525.2M	↓ 17.45%
Net Profit Margin	-180.51%	↑ 959.12%

	FY24	Y/Y Change
Revenue	$363.6M	↑ 36.34%
Net Income	$-378.1M	↓ 21.47%
Net Profit Margin	-103.97%	↑ 76.54%

	Q3 FY23	Q/Q Change
Revenue	$51.3M	↑ 1.35%
Net Income	$-173.2M	↑ 33.59%
Net Profit Margin	-337.73%	↓ 81.5%

	Q4 FY23	Q/Q Change
Revenue	$104.6M	↑ 99.64%
Net Income	$-142.9M	↓ 19.23%
Net Profit Margin	-136.65%	↑ 201.08%

	Q1 FY24	Q/Q Change
Revenue	$39.1M	↓ 62.46%
Net Income	$-118.9M	↓ 16.53%
Net Profit Margin	-303.85%	↓ 167.2%

	Q2 FY24	Q/Q Change
Revenue	$38.7M	↑ 0.0%
Net Income	$-117.7M	↑ 0.0%
Net Profit Margin	-303.85%	↑ 0.0%

	Q3 FY24	Q/Q Change
Revenue	$57.8M	↑ 60.66%
Net Income	$-99.2M	↓ 9.31%
Net Profit Margin	-171.52%	↑ 132.33%

	Q4 FY24	Q/Q Change
Revenue	$173.9M	↑ 200.72%
Net Income	$-38.5M	↓ 61.22%
Net Profit Margin	-22.12%	↑ 149.4%

	FY19	Y/Y Change
Profit	$14.9M	↑ 26.41%

	FY20	Y/Y Change
Profit	$8.5M	↓ 48.01%

	FY21	Y/Y Change
Profit	$4.8M	↓ 38.8%

	FY22	Y/Y Change
Profit	$41.3M	↑ 817.44%

	FY23	Y/Y Change
Profit	$242.5M	↑ 469.52%

	FY24	Y/Y Change
Profit	$319.4M	↑ 43.66%

	Q3 FY23	Q/Q Change
Profit	$43.4M	↑ 17.94%

	Q4 FY23	Q/Q Change
Profit	$96.4M	↑ 117.3%

	Q1 FY24	Q/Q Change
Profit	$26.7M	↓ 72.22%

	Q2 FY24	Q/Q Change
Profit	$26.4M	↑ 0.0%

	Q3 FY24	Q/Q Change
Profit	$46.6M	↑ 90.08%

	Q4 FY24	Q/Q Change
Profit	$159.9M	↑ 242.88%

	FY19	Y/Y Change
Operating Cash Flow	$-195.5M	↑ 26.75%
Investing Cash Flow	$-5.7M	↑ 94.83%
Financing Cash Flow	$548.5M	↑ 142.83%

	FY20	Y/Y Change
Operating Cash Flow	$-330.3M	↑ 54.34%
Investing Cash Flow	$-354.2M	↑ 5544.49%
Financing Cash Flow	$733.0M	↑ 22.09%

	FY21	Y/Y Change
Operating Cash Flow	$-472.1M	↑ 53.8%
Investing Cash Flow	$-125.0M	↓ 62.03%
Financing Cash Flow	$397.2M	↓ 41.69%

	FY22	Y/Y Change
Operating Cash Flow	$-524.6M	↑ 18.69%
Investing Cash Flow	$65.3M	↓ 155.83%
Financing Cash Flow	$419.9M	↑ 12.92%

	Q1 FY23	Q/Q Change
Operating Cash Flow	$-163.9M	↑ 8.08%
Investing Cash Flow	$50.3M	↓ 5991.72%
Financing Cash Flow	$-2.5M	↓ 271.16%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-166.1M	↑ 0.0%
Investing Cash Flow	$50.9M	↑ 0.0%
Financing Cash Flow	$-2.5M	↑ 0.0%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-133.1M	↓ 18.55%
Investing Cash Flow	$23.7M	↓ 52.68%
Financing Cash Flow	$153.0M	↓ 6308.66%

Ascendis Pharma A/s Technicals Summary

Sell

Neutral

Buy

Ascendis Pharma A/s is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Ascendis Pharma A/s (ASND) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ascendis Pharma A/s	6.31%	8.23%	15.13%	48.82%	64.0%
Alnylam Pharmaceuticals, Inc.	1.38%	-8.28%	71.25%	56.03%	155.84%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ascendis Pharma A/s	NA	NA	NA	-3.28	-8.18	-0.17	NA	-1.77
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.52	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ascendis Pharma A/s	Buy	$9.9B	64.0%	NA	-103.97%
Alnylam Pharmaceuticals, Inc.	Buy	$31.6B	155.84%	NA	-12.37%

Ascendis Pharma A/s Dividend announcements

Ascendis Pharma A/s Earnings
Ascendis Pharma A/s’s price-to-earnings ratio stands at None

About Ascendis Pharma A/s

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Organization	Ascendis Pharma A/s
Employees	1017
CEO	Mr. Jan Moller Mikkelsen
Industry	Health Technology

Management People of Ascendis Pharma A/s

Name	Title
Mr. Jan Moller Mikkelsen	President, CEO, Member of Executive Board & Executive Director
Mr. Scott T. Smith	CFO, Executive VP & Member of Executive Board
Ms. Lotte Sonderbjerg	Executive VP, Chief Administrative Officer & Member of the Executive Board
Mr. Michael Wolff Jensen L.L.M.	Executive VP, Chief Legal Officer & Member of the Executive Board
Mr. Mads Bodenhoff	Senior VP, Head of Finance & Principal Accounting Officer
Mr. Timothy J. Lee	Senior Director of Investor Relations
Mr. Flemming Steen Jensen	Executive Vice President of Product Supply & Quality
Dr. Kennett Sprogoe Ph.D.	Executive VP and Head of Research & Product Development
Dr. Stina Singel M.D., Ph.D.	Executive VP & Head of Clinical Development for Oncology
Mr. Joseph Kelly	Head of U.S. Commercial of Endocrinology

Important FAQs about investing in ASND Stock from India :

What is Ascendis Pharma A/s share price today?

Ascendis Pharma A/s share price today stands at $166.05, Open: $164.29 ; Previous Close: $164.65 ; High: $166.86 ; Low: $161.25 ; 52 Week High: $169.37 ; 52 Week Low: $111.09.

The stock opens at $164.29, after a previous close of $164.65. The stock reached a daily high of $166.86 and a low of $161.25, with a 52-week high of $169.37 and a 52-week low of $111.09.

Can Indians buy Ascendis Pharma A/s shares?

Yes, Indians can invest in the Ascendis Pharma A/s (ASND) from India.

With INDmoney, you can buy Ascendis Pharma A/s at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Ascendis Pharma A/s at zero transaction cost.

How can I buy Ascendis Pharma A/s shares from India?

It is very easy to buy Ascendis Pharma A/s from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Ascendis Pharma A/s (ASND) be purchased?

Yes, you can buy fractional shares of Ascendis Pharma A/s with INDmoney app.

What are the documents required to start investing in Ascendis Pharma A/s stocks?

To start investing in Ascendis Pharma A/s, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.